Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 277, Issue 6 46-6, 1999, Pages

  Tang, Xiaoping ^a   Mohuczy, Dagmara ^a   Zhang, Y Clare ^a   Kimura, Birgitta ^a   Galli, Sara M ^a   Phillips, M Ian ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adeno associated virus; H4 II E cells; Inbred spontaneously hypertensive rats

Indexed keywords

ANGIOTENSINOGEN;

ADENO ASSOCIATED VIRUS; ANGIOTENSIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CYTOMEGALOVIRUS; GENE MUTATION; GENE OVEREXPRESSION; GENE THERAPY; HYPERTENSION; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASOCONSTRICTION;

EID: 0033370798     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1999.277.6.h2392     Document Type: Article

References (42)

1. Bartlett, J. S., and R. J. Samulski. Adeno-associated virus vectors for human gene therapy. In: Gene Therapy, edited by N. R. Lemoine and D. H. Cooper. Oxford, UK: BIOS Scientific Publishers, 1996, p. 77-92.
2. Bartlett, R. J., S. L. Secore, J. T. Singer, M. Bodo, K. Sharma, and C. Ricordi. Long-term expression of a fluorescent reporter gene via direct injection of plasmid vector into mouse skeletal muscle: comparison of human creatine kinase and CMV promoter expression levels in vivo. Cell Transplant. 5: 411-419, 1996.
3. Baudard, M., T. R. Flotte, M. Aran, A. L. Thierry, I. Pastan, M. Pang, W. G. Kearns, and M. M. Gottesman. Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposome. Hum. Gene Ther. 7: 1309-1322, 1996.
4. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye biding. Anal. Biochem. 72: 514-517, 1976.
5. Chattrejee, S., P. R. Johnson, and K. K. Wong. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science 258: 1485-1488, 1992.
6. Covene, Y., B. Clary, M. Lacobucci, R. Philip, and K. Lyerly. Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals. Surgery 120: 265-273, 1996.
7. Fan, L., J. Drew, M. G. Dunckley, J. S. Owen, and G. Dickson. Efficient coexpression and secretion of anti-atherogenic human apolipoprotein A1 and lecithin-cholesterol acyltransferase by cultured muscle cells using adeno-associated virus plasmid vectors. Gene Ther. 5: 1434-1440, 1998.
8. Flotte, T. R., S. A. Afione, R. Solow, M. L. Drumm, D. Markakis, W. B. Guggino, P. L. Zeitlin, and B. J. Carter. Expression of cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J. Biol. Chem. 268: 3781-3790, 1993.
9. Flotte, T. R., S. A. Afione, and P. L. Zeitlin. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am. J. Respir. Cell Mol. Biol. 11: 517-521, 1994.
10. Fukamizu, A., K. Sugimura, E. Takimoto, F. Sugiyama, M. S. Seo, S. Takahashi, T. Hatae, N., Nakajima, K. Yagami, and K. Murakami. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J. Biol. Chem. 268: 11617-11621, 1993.
11. Ganten, D., K. Hermann, C. Bayer, T. Unger, and R. E. Lang. Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science 221: 869-871, 1983.
12. 1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul. Pept. 49: 167-174, 1993.
13. Helene, C., and J. J. Toulme. Specific regulation of gene expression by antisense, sense, and antigene nucleic acids. Biochim. Biophys. Acta 1049: 99-125, 1990.
14. Hofland, H. E., D. Nagy, J. J. Liu, K. Spratt, Y. L. Lee, O. Danos, and S. M. Sullivan. In vivo gene transfer by intravenous administration of stable cationic lipid/DNA complex. Pharm. Res. 14: 742-749, 1997.
15. Jeunemaitre, X., F. Soubrier, Y. V. Kotelevetsev, R. P. Lifton, C. S. Williams, A. Chiaru, S. C. Hunt, P. N. Hopkins, R. R. Williams, J. M. Lalouel, and P. Corvol. Molecular basis of human hypertension: role of angiotensinogen. Cell 71: 169-180, 1992.
16. Kimura, S., J. J. Mullins, B. Bunnemann, R. Metzger, U. Hilgenfeldt, F. Zimmermann, H. Jacob, K. Fuxe, D. Ganten, and M. Kaling. High blood pressure in transgenic mice carrying the rat angiotensinogen gene. EMBO J. 11: 821-827, 1992.
17. Lebkowski, J. S., T. B. Okarma, and R. Philip. The challenges of recombinant adeno-associated virus manufacturing: alternative use of adeno-associated virus plasmid/liposome complexes for gene therapy applications. Curr. Top. Microbiol. Immunol. 218: 51-59, 1996.
18. Lynch, K. R., and M. J. Peach. Molecular biology of angiotensinogen. Hypertension 17: 263-269, 1991.
19. Lynch, K. R., V. I. Simnad, E. T. Ben Ari, and J. C. Garrison. Localization of preangiotensinogen messenger RNA sequences in the rat brain. Hypertension 8: 540-543, 1986.
20. Makino, K., M. Sugano, S. Ohtsuka, and S. Sawada. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension 31: 1166-1170, 1998.
21. McLean, J. W., E. A. Fox, P. Baluk, P. B. Bolton, A. Haskell, R. Pearlman, G. Thurston, E. Y. Umemoto, and D. M. McDonald. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am. J. Physiol. 273 (Heart Circ. Physiol. 42): H387-H404, 1997.
22. Mohuczy, D., C. Gelband, and M. I. Phillips. Antisense inhibition of AT1 receptors in vascular smooth muscle cells using adeno-associated virus-based vector. Hypertension 33: 354-359, 1999.
23. Mohuczy, D., and M. I. Phillips. Adeno-associated virus vector as a highly efficient transporter of exogenous DNA into cells (Abstract). FASEB J. 10: A447, 1996.
24. Neckers, L., L. Whitsell, A. Rosolen, and D. A. Geselowitz. Antisense inhibition of oncogene expression. Crit. Rev. Oncog. 3: 175-231, 1992.
25. Ohkubo, H., H. Kawakami, Y. Kakechi, T. Takumi, H. Arai, Y. Yokota, M. Iwai, Y. Tanabe, M. Masu, H. Iwao, H. Okamoto, M. Yokoyama, T. Nomura, M. Katsuki, and S. Nakanishi. Generation of transgenic mice with elevated blood pressure by introduction of the rat renin and angiotensinogen genes. Proc. Natl. Acad. Sci. USA 87: 5153-5157, 1990.
26. Osaka, G., K. Carey, A. Cuthbertson, P. Godowski, T. Patapoff, A. Ryan, T. Gadek, and J. Mordenti. Pharmacokinetics, tissue distribution, and expression efficiency of plasmid [33P] DNA following intravenous administration of DNA/cationic lipid complexes in mice: use of a novel radionuclide approach. J. Pharm. Sci. 85: 612-618, 1996.
27. Pardridge, W. M. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 70: 1781-1792, 1998.
28. Philip, R., E. Brunette, L. Kilinski, D. Murugesh, M. A. Mcnally, K. Ucar, J. Rosenblatt, T. B. Okarma, and J. S. Lebkowski. Efficient and sustained gene expression in primary T lymphocytes and primary and cultured cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol. Cell. Biol. 14: 2411-2418, 1994.
29. Phillips, M. I. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension 29: 177-187, 1997.
30. Phillips, M. I. Is gene therapy for hypertension possible? Hypertension 33: 8-13, 1999.
31. Phillips, M. I., E. A. Speakman, and B. Kimura. Levels of angiotensin and molecular biology of tissue renin-angiotensin system. Regul. Pept. 43: 1-20, 1993.
32. Shafron, D. R., C. E. Simpkins, B. Jebelli, A. L. Day, and E. M. Meyer. Reduced MK801 binding in neocortical neurons after AAV-mediated transfections with NMDA-R1 antisense cDNA. Brain Res. 784: 325-328, 1998.
33. Tamura, K., S. Umerura, A. Fukamizu, M. Ishii, and K. Murakami. Recent advances in the study of renin and angiotensinogen genes: from molecules to the whole body. Hypertens. Res. 18: 7-18, 1995.
34. Tang, F., and J. A., Hughes. Introduction of a disulfide bond into a cationic lipid enhances transgene expression of plasmid DNA. Biochem. Biophys. Res. Commun. 242: 141-145, 1998.
35. Thomas, W. G., and C. Sernia. Immunocytochemical localization of angiotensinogen in the rat brain. Neuroscience 25: 319-341, 1988.
36. Tomita, N., R. Morishita, J. Higaki, M. Aoki, Y. Nakamura, H. Mikami, A. Fukamizu, K. Murakami, Y. Kaneda, and T. Ogihara. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 26: 131-136, 1995.
37. Vieweg, J., D. Boczkowski, K. M. Roberson, D. M. Edwards, M. Philip, R. Philip, T. Rudoll, C. Smith, C. Robertson, and E. Gilboa. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res. 55: 2366-2372, 1995.
38. Wahiestedt, C., E. Golanov, F. Yamamoto, and F. Yee. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature 363: 260-263, 1993.
39. Wang, S., W. J. Millard, and E. M. Meyer. NGF gene expression in dividing and non dividing cells from AAV-derived constructs. Neurochem. Res. 23: 779-786, 1998.
40. Warrington, K. H., C. Teschendorf, L. Cao, N. Muzyczka, and D. W. Siemann. Developing VDEPT for DT-dlaphorase (NQO1) using an AAV vector plasmid. Int. J. Radiat. Oncol. Biol. Phys. 42: 909-912, 1998.
41. Wielbo, D., A. Simon, M. I. Phillips, and S. Toffolo. Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension 28: 147-151, 1996.
42. Yongue, B. G., J. A. Angolo, B. S. Mceween, and M. M. Meyers. Brain and liver agiotensinogen messenger RNA in genetic hypertensive and normotensive rats. Hypertension 17: 485-491, 1997.